Pregabalin Alternatives Compared
Pregabalin | Qulipta | Topamax |
|
---|
Pregabalin | Qulipta (atogepant) | Topamax (topiramate) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Pregabalin is used in the treatment of nerve pain and also to prevent seizures. Drowsiness or dizziness are common side effects, and it has the potential to be misused. Prescribed for Neuropathic... View more |
Prescription only
Prescribed for Migraine Prevention. Qulipta may also be used for purposes not listed in this medication guide. |
Prescription only
Topamax may be prescribed either alone or in combination with other medications for the treatment of certain types of epilepsy, or it may be given for the prevention of migraine. Drowsiness is a... View more |
Related suggestions Migraine Prevention (Migraine Prophylaxis)
|
|||||||||||||||||||||||
More about Pregabalin | More about Qulipta (atogepant) | More about Topamax (topiramate) | ||||||||||||||||||||||||
Generic Status | ||||||||||||||||||||||||||
No lower-cost generic available |
||||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Pregabalin has an average rating of 6.7 out of 10 from a total of 1564 ratings on Drugs.com. 57% of reviewers reported a positive effect, while 25% reported a negative effect. |
Qulipta has an average rating of 6.0 out of 10 from a total of 36 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 30% reported a negative effect. |
Topamax has an average rating of 6.2 out of 10 from a total of 624 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Commonly reported side effects include:
See also: pregabalin side effects in more detail. |
See also: Qulipta side effects in more detail. |
Common side effects include:
See also: Topamax side effects in more detail. |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all pregabalin prices |
View all Qulipta prices |
View all Topamax prices and generic prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Lyrica, Lyrica CR |
N/A |
Other topiramate brands include: Eprontia, Qudexy XR, Trokendi XR | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
6.3 hours |
11 hours |
56 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 280 drugs are known to interact with pregabalin:
|
A total of 166 drugs are known to interact with Qulipta:
|
A total of 285 drugs are known to interact with Topamax:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
September 28, 2021 |
December 24, 1996 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.